Posted: Tue May 26, 2009 10:32 pm Post subject: NanoViricides, Inc. Announces Influenza Testing Agreement fo
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide™, NanoViricides’ universal anti-influenza drug candidate.
The study will initially evaluate effectiveness of nanoviricide™ drug candidates against a virulent H1N1 strain which caused a severe outbreak in 1930. This well-characterized virus is expected to be a good surrogate for the current 2009 H1N1 influenza (“swine flu”) that is in the pre-pandemic stage according to the WHO. The study will then be expanded to include other influenza subtypes that are feared to be on the horizon, such as H3N2.
The Company has previously reported that a prior version of FluCide drug candidate was superior in its effect by a very large margin when compared to oseltamivir (TamifluŽ, Roche) in an animal study. The Company has also previously reported that the same drug candidate was highly effective in cell culture studies against two different kinds of H5N1 bird flu virus, namely Vietnam 2004 Clade I virus, and Vietnam 2006 Clade II virus. The latter is closely related to the Indonesia 2006 H5N1 virus that is currently causing human fatalities in Indonesia.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum